Medivation Inc (MDVN)

pos +0.49
Today's Range: 62.05 - 63.16 | MDVN Avg Daily Volume: 2,788,400
Last Update: 07/25/16 - 3:59 PM EDT
Volume: 1,368,333
YTD Performance: 29.56%
Open: $62.77
Previous Close: $62.63
52 Week Range: $26.41 - $63.35
Oustanding Shares: 164,624,777
Market Cap: 10,295,633,554
6-Month Chart
TheStreet Ratings Grade for MDVN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 9 9 11
Moderate Buy 0 0 0 0
Hold 4 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.62 1.62 1.62 1.53
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 39.58
Price Earnings Comparisons:
MDVN Sector Avg. S&P 500
39.58 41.60 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
18.98% 14.23% 120.02%
Revenue 32.80 4.20 0.72
Net Income -11.50 -6.90 0.00
EPS -14.00 -6.50 0.00
Earnings for MDVN:
Revenue 0.94B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $0.22 $0.31 $0.95 $2.15
Number of Analysts 7 2 2 2
High Estimate $0.26 $0.31 $1.00 $2.48
Low Estimate $0.18 $0.30 $0.90 $1.83
Prior Year $0.23 $0.27 $0.68 $0.95
Growth Rate (Year over Year) -6.38% 12.96% 39.71% 126.84%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
All of these add up to a level of insecurity on the part of sidelined money.
It's a pretty broad spectrum, but they've definitely arrived.
The uptick in the small- and mid-cap space bodes well for future capital appreciation.
FDA decision will impact Relypsa's buyout potential while Aritana won't stay this undervalued.
It is hard to see much growth in the market overall, until earnings growth returns.
May 09, 2016 | 7:57 AM EDT
MDVN was upgraded to Buy, Citigroup said. $73 price target. Xtandi also now appears to be effective against breast cancer.
Checking the gauges for underperformance, none of them look good.
Apr 19, 2016 | 7:03 AM EDT
MDVN was upgraded from Hold to Buy, Canaccord Genuity said. $70 price target. Breast and Ovarian cancer treatments can drive growth.&nb...
Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.

Columnist Conversations

View Chart »  View in New Window » The S&P futures has held on top of a key symmetrical pr...
we are out of AAPL here as this one looks suspect. we'll cut this one here as the price action, technica...
Occidental is trading at new July lows this morning.  The stock is off just shy of 1.5% as the current pu...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.